Clinical trials
UTUC clinical trials
Below are recruiting utuc clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07741448RecruitingPhase 2
Chemo and targeted drug before surgery for HER2-positive upper tract cancer
This trial tests a combination of chemotherapy (gemcitabine) and a targeted drug (Trastuzumab Rezetecan) before surgery to remove the kidney and ureter. It may help shrink the tumor and improve outcomes for people with HER2-positive upper tract urothelial cancer.
Huanggang, HubeiAges 18–75 - NCT06668493RecruitingPhase 1/Phase 2
A virus-based treatment for low-grade upper tract bladder cancer
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
Scottsdale, ArizonaAges 18 years+ - NCT05731622Recruiting
Mitomycin C in the bladder after ureteroscopy for UTUC
This trial studies whether a medicine called mitomycin C given as a one-time bladder treatment right after ureteroscopy can reduce later recurrence (measured by urine test results and “IVR rate”). It may help people with non-spreading UTUC who are having endoscopic procedures and are planned for this standard add-on treatment.
AmsterdamAges 18 years+ - NCT05438537Recruiting
Study of effects of surgery in upper urinary tract cancer
This study looks at what happens in and around the time of surgery for upper tract urothelial cancer. It may help doctors better understand how the disease and the body respond to treatment.
Hong KongAges 18 years+ - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05837806RecruitingPhase 2
Tislelizumab and disitamab as pre-surgery treatment for HER2 UTUC
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
TianjinAges 18 years+ - NCT06652009Recruiting
Radiation vs surgery for kidney and ureter cancer
This study compares two treatments for cancer of the kidney pelvis or ureter: radiation therapy (using high-energy beams) versus surgery. It is for people who cannot have surgery for medical reasons and want to see if radiation could be a good alternative.
BeijingAges 18–80 - NCT07126119RecruitingPhase 2
Immunotherapy plus chemo before surgery for upper tract cancer
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
Tianjin, Outside U.S.Ages 18 years+ - NCT06848868RecruitingPhase 1
Clinic-based scope for bladder cancer follow-up
This trial tests if a procedure done in the clinic, without general anesthesia, can safely check the upper urinary tract after kidney-sparing surgery for urothelial cancer. It may reduce the need for hospital visits.
Hong KongAges 18 years+ - NCT06987552Recruiting
Single-Incision Robotic Surgery for Upper Urinary Tract Cancer
This study tests a new, less invasive robotic surgery using a single small incision to remove the kidney and the upper part of the ureter (the tube connecting the kidney to the bladder) in people with upper tract urothelial cancer. It may offer a faster recovery with fewer side effects compared to traditional surgery.
TaipeiAges 20 years+ - NCT05912816RecruitingPhase 2
Kidney-protecting treatment for high-risk upper urinary tract cancer
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07321210Recruiting
Lymph node surgery for high-risk upper tract cancer
This trial compares removing the kidney and ureter alone versus also removing nearby lymph nodes for high-risk upper tract urothelial cancer. It aims to see if the extra step helps improve outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06167057Recruiting
Chemotherapy after scope for upper urinary tract cancer
This study is testing whether giving a single dose of chemotherapy directly into the kidney and ureter right after a scope procedure helps prevent upper urinary tract tumors from coming back. It’s for people who are about to have a scope to diagnose or treat a suspected or known tumor in the upper urinary tract.
AshdodAges 18 years+ - NCT07225374RecruitingPhase 2
Avelumab after chemotherapy for upper tract urothelial cancer
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Seoul, GangnamAges 20 years+ - NCT05874921Recruiting
Registry for adults with UTUC treated with Jelmyto
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
Santa Monica, CaliforniaAges 18 years+ - NCT05917158RecruitingPhase 2
HER2-targeted drug study after kidney/ureter tumor surgery
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
Nanjing, JiangsuAges 18 years+ - NCT06120374Recruiting
Immunotherapy plus radiation after surgery for upper tract cancer
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
BeijingAges 18 years+ - NCT06354231RecruitingPhase 2
Kidney-sparing combo for high-risk ureter cancer
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
ShanghaiAges 18 years+ - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT06652022Recruiting
Radiation plus drugs vs drugs alone for limited spread bladder cancer
This trial tests whether adding targeted radiation to standard drug therapy can help people with a limited number of bladder or urinary tract cancer metastases. It's for those whose cancer has spread to a few spots that can be treated with full coverage radiation.
BeijingAges 18–80 - NCT06991868Recruiting
Urine test to monitor for urothelial cancer recurrence
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Beijing, Beijing MunicipalityAges 1.5 years+ - NCT07614594Recruiting
Urine Test to Detect Bladder and Kidney Cancer
This study tests whether a simple urine test can accurately identify cancer in the bladder, ureters (tubes between kidneys and bladder), or renal pelvis (part of the kidney). You would provide urine samples before your planned surgery, and researchers will compare the urine test results to your actual tissue diagnosis after surgery.
Zhengzhou, HenanAges 18 years+
Hear when a new UTUC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for utuc?
- Yes. Clin2 currently lists 22 recruiting utuc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a utuc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a utuc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.